Myoridge specializes in the development of high-purity myocardial cells with optimized culture media, enhancing drug response rates for cardiac research and therapies. The company addresses the challenge of inefficient cell culture processes in regenerative medicine by providing tailored media solutions and comprehensive support for cell-based product development.
Funding
$8.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cell-based research and therapies are often hindered by inefficient cell culture processes and the lack of optimized media, leading to inconsistent drug response rates and challenges in regenerative medicine product development. Traditional cell culture methods may not adequately support the specific needs of specialized cells like cardiomyocytes, impacting the reliability and reproducibility of experimental results.
Solution
Myoridge provides high-purity cell culture solutions, specializing in optimized culture media for various cell types, including myocardial cells and T-cells. The company addresses the limitations of standard cell culture by offering tailored media formulations and comprehensive support for cell-based product development. Myoridge leverages its proprietary media component library and cell culture expertise to optimize cell growth, differentiation, and functionality. Their services include media development, optimization, and consulting to improve cell culture outcomes. Myoridge also supports the development of in vitro models for drug discovery and regenerative medicine applications, offering contract services for iPS cell differentiation and cell-based assays.
Target Audience
Myoridge serves researchers in academia and industry, as well as companies developing cell-based therapies, regenerative medicine products, and in vitro models for drug discovery.
Features
- Serum-free, functional media for various cell types, including cardiomyocytes, MSCs, and T-cells
- Proprietary media component library for customized media formulations
- Media optimization services to address specific cell culture challenges
- Support for regenerative medicine and cell therapy product development
- In vitro model development for drug screening and efficacy testing
- Contract services for iPS cell differentiation and cell-based assays
- AI-driven media development for mesenchymal stem cells (MSCs)